Knockdown of Linc00152 Inhibits the Progression of Gastric Cancer by Regulating MicroRNA-193b-3p/ETS1 Axis
Overview
Pharmacology
Affiliations
Background: Gastric cancer (GC) is a serious threat for public health worldwide. Long non-coding RNA (lncRNA) linc00152 has been well reported to be an oncogene and a potential biomarker in multiple cancers including GC. However, the molecular mechanisms of linc00152 in GC development need to be further investigated.
Methods: RT-qPCR assay was employed to detect the levels of linc00152, microRNA-193b-3p (miR-193b-3p) and ETS1 mRNA. ETS1 protein level was measured by western blot assay. Cell proliferative, migratory and invasive capacities were assessed by colony formation together with CCK-8 assays, transwell migration and invasion assays, respectively. Bioinformatics analyses and luciferase reporter assay were used to explore whether miR-193b-3p could interact with linc00152 or ETS1 3'UTR. The roles and molecular basis of linc00152 silence on the growth of GC xenograft tumors were tested in vivo.
Results: Linc00152 expression was notably upregulated in GC tissues and cells. The proliferative, migratory and invasive abilities of GC cells were weakened by linc00152 depletion, miR-193b-3p overexpression or ETS1 knockdown. Linc00152 upregulation inhibited miR-193b-3p expression by direct interaction and abolished miR-193b-3p-mediated anti-proliferation, anti-migration and anti-invasion effects in GC cells. ETS1 was a target of miR-193b-3p and linc00152 could promote ETS1 expression by downregulating miR-193b-3p. In vivo experiments further validated that linc00152 knockdown inhibited the growth of GC xenograft tumors by upregulating miR-193b-3p and downregulating ETS1.
Conclusion: Knockdown of linc00152 inhibited GC progression by sequestering miR-193b-3p from ETS1 in vitro and in vivo, elucidating a novel molecular mechanism of linc00152 in promoting GC carcinogenesis.
Silva J, Teixeira E, Mourao R, Ferraz R, Moreira F, Assumpcao P Front Pharmacol. 2023; 14:1237723.
PMID: 37670949 PMC: 10476871. DOI: 10.3389/fphar.2023.1237723.
Lin H, Ni R, Li D, Zhao M, Li Y, Li K Int J Med Sci. 2023; 20(7):933-942.
PMID: 37324190 PMC: 10266045. DOI: 10.7150/ijms.82216.
Wen X, Sun X, Ou Z, Jiang J, Chen Q, He X Acta Biochim Biophys Sin (Shanghai). 2022; 54(10):1441-1452.
PMID: 36305724 PMC: 9828152. DOI: 10.3724/abbs.2022148.
Li T, Xing G, Lu L, Kong X, Guo J Evid Based Complement Alternat Med. 2022; 2022:6370766.
PMID: 35958928 PMC: 9357677. DOI: 10.1155/2022/6370766.
Kulkarni A, Gayathrinathan S, Nair S, Basu A, Al-Hilal T, Roy S Cells. 2022; 11(15).
PMID: 35954293 PMC: 9367924. DOI: 10.3390/cells11152448.